Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer
About This Grant
PROJECT SUMMARY Prostate cancer is the most prevalent cancer among US veterans, and the Veterans Affairs Health System (VA) cares for 15,000 new cases each year. Castration-resistant prostate cancer (CRPC) is difficult to treat, typically requiring toxic chemotherapies which achieve only modest benefit. Unfortunately, progress has been slow, and there has been a drought of new treatments for CRPC. Radioligand therapy (therapeutic radioactive isotopes targeted to malignant cells) is a new, effective class of treatments for CRPC. In 2022 Lutetium Lu-177 vipivotide tetraxetan (Lu-177) became the first FDA-approved radioligand for CRPC after demonstrating improved overall survival and reduced toxicity in clinical trials. Due to these promising results, Lu-177’s approval was met with great excitement from both providers and patients. However, access to Lu-177 therapy within the Veterans Affairs Health System (VA) is unknown. The high infrastructure requirements necessary to administer Lu-177 may cause access barriers; the VA has far fewer sites capable of administering Lu-177 compared to non-VA providers. The VA Community Care program (VACC) – in which the VA pays for veterans to receive care from non-VA providers – may help mitigate access barriers, but the VACC has faced prolonged wait times and quality-of-care concerns. In addition, the clinical outcomes of Lu-177 within the veteran population have not been evaluated; clinical trial results often fail to generalize to real-world patient populations that are typically older and more comorbid than those enrolled on trials, resulting in diminished survival benefit and increased toxicity. To address these knowledge gaps, we propose to describe access to and outcomes of Lu-177 therapy among US veterans. We will apply national, Medicare-linked VA data to identify veterans diagnosed with prostate cancer and measure care delivered by both VA and non-VA providers to achieve a comprehensive understanding of veteran access and outcomes. Aim 1: Measure adoption and access to Lu-177 therapy for US veterans. Using national VA data linked to Medicare claims, we will compare Lu-177 adoption within the VA to non-veteran patients treated in community settings (Flatiron Health) (Aim 1A), and assess geographic and income-based access barriers within the VA (Aim 1B). Aim 2: Measure clinical outcomes of Lu-177 therapy among US veterans. We will measure overall survival (Aim 2A) and treatment toxicity (Aim 2B) among veterans treated with Lu-177, compared to clinical trial participants and to non-veteran patients treated in community settings. Aim 3: Evaluate the role of VA Community Care in providing access to Lu-177 therapy. We will measure access to (Aim 3A) and outcomes of (Aim 3B) Lu-177 therapy for veterans receiving treatment within VA facilities vs. via VACC.
Grant Summary
Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer is a NCI - National Cancer Institute grant providing up to $708K for university, nonprofit, healthcare org. Applications are due 2031-07-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $708K
2031-07-31
- 1Confirm your organization is eligible for Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer: Frequently Asked Questions
Who is eligible for the Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer?
Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer provide?
Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer provides up to $708K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer deadline?
Applications for Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer are due 2031-07-31 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer?
To apply for Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.